New drug combo aims to tame tough lymphoma, paving way for transplant
NCT ID NCT05852717
Summary
This study is testing a new combination of drugs for adults whose aggressive large B-cell lymphoma has returned or stopped responding to standard treatment. The goal is to see if adding a drug called epcoritamab to a standard chemotherapy regimen (GDP) is safe and effective at shrinking the cancer. If successful, this treatment aims to control the disease so patients can potentially proceed to a stem cell transplant or CAR T-cell therapy, which are more definitive treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Contact
-
Karmanos Cancer Center (Wayne State University)
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact
Contact Email: •••••@•••••
-
University of Virginia Health System
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.